Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis
University of Kansas Medical Center
42 participants
Jun 3, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to test use of losartan in those with cystic fibrosis (CF) on modulator therapy. The main question it aims to answer is if treatment with losartan improves response of the CF transmembrane conductance regulator (CFTR) channel to modulator therapy. Participants will be asked take losartan or placebo for twelve weeks and will have changes in sweat chloride levels measured as a marker of CFTR function.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Treatment with losartan through week 12
Treatment with placebo through week 12
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06364176